(NASDAQ: CNTA) Centessa Pharmaceuticals's forecast annual revenue growth rate of 116.16% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 83.92%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.62%.
Centessa Pharmaceuticals's revenue in 2025 is $15,000,000.On average, 8 Wall Street analysts forecast CNTA's revenue for 2025 to be $2,011,101,540, with the lowest CNTA revenue forecast at $2,011,101,540, and the highest CNTA revenue forecast at $2,011,101,540. On average, 3 Wall Street analysts forecast CNTA's revenue for 2028 to be $9,197,437,710, with the lowest CNTA revenue forecast at $8,661,143,966, and the highest CNTA revenue forecast at $9,787,360,828.
In 2029, CNTA is forecast to generate $39,668,977,877 in revenue, with the lowest revenue forecast at $24,937,659,096 and the highest revenue forecast at $61,137,486,816.